Physician profile
Thomas A Manning
NPI 1447204490
$11,470.09
in general payments reported to CMS, 2019-2025
27 companies · $2,161 in 2025
The $2,161 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,547 · 2020: $867 · 2021: $1,498 · 2022: $1,623 · 2023: $1,681 · 2024: $2,093 · 2025: $2,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,580 · Education: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,579.71 |
| Education | $354.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,211.24 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,837.86 | 2019-2025 | |
| Lilly USA, LLC | $1,426.50 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,308.73 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $938.27 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Janssen Biotech, INC. | $876.96 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $747.69 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $407.53 | 2021-2025 | Bimzelx |
| Pfizer INC. | $389.28 | 2019-2025 | |
| Genzyme Corporation | $329.36 | 2019-2025 | |
| Amgen INC. | $310.50 | 2019-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.14 | 2022-2024 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $94.96 | 2024-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $90.57 | 2020-2025 | Nemluvio |
| Dusa Pharmaceuticals, INC. | $85.98 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $68.39 | 2023-2024 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.49 | 2019 | |
| Celgene Corporation | $42.88 | 2019 | |
| Organon LLC | $34.99 | 2024-2025 | Vtama |
| Journey Medical Corporation | $23.52 | 2019 | |
| Arcutis Biotherapeutics, INC. | $22.94 | 2024 | Zoryve |
| Sandoz INC. | $17.36 | 2025 | Hyrimoz |
| Dermavant Sciences, INC. | $14.38 | 2024 | Vtama |
| Aclaris Therapeutics, INC. | $13.05 | 2019 | |
| Mission Pharmacal Company | $12.49 | 2019 | |
| Dermira, INC. | $11.96 | 2019 | |
| Prugen, INC. Pharmaceuticals | $7.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Manning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.